based the recommendation on literature review, their own experiences and input from other experts. Recently, a panel of cytopathologists and surgical pathologists has proposed a set of guidelines for salivary gland cytopathology designated as the Milan System for Reporting of Salivary Gland Cytopathology (MSRSGC). 6 The MSRSGC contains six diagnostic categories, one of which is subdivided into two subcategories (Table 1) published a study of 171 FNAs of salivary gland nodules. 8 Each FNA had surgical pathology follow-up and diagnostic sensitivity and specificity for the separation of benign from malignant lesions was calculated. In the original series, the ultimate goal of the cytopathologists was to replicate surgical pathology type diagnoses as closely as possible and avoid a system using broadly defined categories. Whenever possible, a very specific histopathological diagnosis was made rather than a more broadly-based categorisation. Thus, whenever possible, a diagnosis of pleomorphic adenoma was made rather than a categorical diagnosis of neoplasm, benign, and a diagnosis of chronic sialadenitis was made rather than a categorisation of benign, non-neoplastic.
In the current study, one of the authors (L.J.L.) has reviewed the available original slides and assigned them to one of the MSRSGC 
| RESULTS
The correlation of the original cytological diagnoses with the histological diagnoses for the 164 cases retrieved from the slide files is documented in Table 2 ; and the correlates of the MSRSGC categorisation with the surgical pathology follow-up are listed in Table 3 .
Both the original categorisation and the MSRSGC had high accuracy in separation of benign from malignant lesions (93.9% and 95.2% respectively). Table 4 gives the malignancy risk for each of the MSRSGC categories.
In 29 cases (18%), a specimen was designated as non-diagnostic by the MSRSGC; of these, only two (2/29, 7%) cases were considered non-diagnostic in the original series and the remaining 27 had diagnoses (27/29, 93%) in the original review (Table 5 ). Of these, 15
(15/27, 55%) were diagnosed as benign salivary gland tissue only and in 11 cases, a specific diagnosis had been given (Table 5 ). In a single case, an original diagnosis of benign neoplasm was given and confirmed histologically as a haemangioma. In 12 cases, the original cytological diagnosis and the surgical pathology diagnosis correlated precisely and in an additional 15 cases, both the original cytological diagnosis and the surgical diagnosis were benign, non-neoplastic conditions. Overall, the MSRSGC categorisation would have delayed T A B L E 1 Categories of the Milan System for salivary gland cytology appropriate additional workup for two cases misclassified in the original cytological review.
The atypia of undetermined significance (AUS) category was used in 15 cases (Table 6 ) and had a malignancy risk higher than that of the non-diagnostic category (19% and 11% respectively). Cases placed in the atypical category included seven benign tumours, all of which were originally cytologically called benign mixed tumours and were confirmed surgically. However, review of these seven cases revealed the smears to contain only myxoid-chondroid stroma without an epithelial component. According to the criteria proposed by the Milan System, they were correctly placed into the AUS category.
In seven cases, the original diagnosis would have resulted in more appropriate follow-up (Table 7) . By contrast, in 10 cases, the MSRSGC categorisation differed from the original diagnosis and the MSRSGC category would have recommended a more appropriate follow-up (Table 8 ). The Milan diagnostic categories and original diagnoses did not correlate in three cases and all three pairs of diagnoses would have resulted in suboptimal therapy (Table 9 ) whether using the MSRSGC or the original diagnoses.
Correlation of the MSRSGC with final surgical pathology diagnosis allowed calculation of the malignancy risk for each category (Table 4) . Malignancy risk ranged from 5% (non-neoplastic) to 93% The malignancy risks associated with the MSRSGC categories are close to those established by Faquin 6 except for the non-neoplastic category. The current study reported a 5% risk of malignancy for the non-neoplastic category, which is lower than prior estimates. The reason for this discrepancy is not known. A possible explanation is that the reviewer preferentially assigned low cellularity specimens to the non-diagnostic category rather than to the non-neoplastic category. This would have potentially assigned some low cellularity malignancies to the non-diagnostic category rather than the nonneoplastic category. Alternatively, the non-neoplastic category contained a relatively small number of cases and a single additional malignant case included in the non-neoplastic category would have doubled the malignancy risk to 10%.
A potential weakness of the present study design was that only a single cytopathologist assigned the MSRSGC categories possibly resulting in observer bias. Despite this, our findings are similar to those of Rohilla et al. 21 Some cases had significantly different diagnoses/diagnostic categories between the original review and the MSRSGC assignment. Such differences could be due to improving diagnostic accuracy on the part of the reviewer (nearly 30 years' additional experience) or the well-documented intraobserver variability seen in many reproducibility studies of cytological material.
Nonetheless, the present study demonstrates how a reviewer would assign cases both under the old system and using the new MSRSGC categories. Since the same author assigned the case diagnoses in both studies using direct review of the original slides, the present study gives a more functional or practical comparison of case assignment to MSRSGC categories than the subjective assignment of published diagnoses to an MSRSGC category by literature review as performed by Wei et al. 7 In conclusion, the MSRSGC appears to maximise clinical discretion and when coupled with appropriate clinical and imaging findings results in optimal follow-up for the majority of patients. The MSRSGC scheme may result in additional diagnostic procedures (seen in 19/164 [12%] cases) that would not have occurred using the original diagnostic philosophy. This potential increase for additional procedures is due to a high number of non-diagnostic cases by MSRSGC. However, the MSRSGC avoided significant misdiagnosis made in two cases (1%) using the original diagnostic system.
Similarly, the categories atypical and SUMP reduced the number of incorrect diagnoses but required greater clinical discretion to obtain optimal treatment. Larger studies with clinical follow-up will be necessary to determine the overall performance of the new MSRSGC for characterisation of salivary gland cytology.
